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One of the biggest challenges for network meta-analysis is inconsistency, which
occurs when the direct and indirect evidence conflict. Inconsistency causes
problems for the estimation and interpretation of treatment effects and treat-
ment contrasts. Krahn and colleagues proposed the net heat approach as a
graphical tool for identifying and locating inconsistencywithin a network of ran-
domized controlled trials. For networks with a treatment loop, the net heat plot
displays statistics calculated by temporarily removing each design one at a time,
in turn, and assessing the contribution of each remaining design to the inconsis-
tency. The net heat plot takes the form of amatrix which is displayed graphically
with coloring indicating the degree of inconsistency in the network. Applied
to a network of individual participant data assessing overall survival in 7531
patients with lung cancer, we were surprised to find no evidence of important
inconsistency from the net heat approach; this contradicted other approaches
for assessing inconsistency such as the Bucher approach, Cochran's Q statistic,
node-splitting, and the inconsistency parameter approach, which all suggested
evidence of inconsistencywithin the network at the 5% level. Further theoretical
work shows that the calculations underlying the net heat plot constitute an arbi-
trary weighting of the direct and indirect evidencewhichmay bemisleading.We
illustrate this further using a simulation study and a network meta-analysis of
10 treatments for diabetes. We conclude that the net heat plot does not reliably
signal inconsistency or identify designs that cause inconsistency.
KEYWORDS
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1 INTRODUCTION
Network meta-analysis (NMA) is an extension of pairwise meta-analysis methods that combines direct and indirect evi-
dence from a network of trials to calculate a treatment effect for every treatment comparison within a single statistical
model. A key assumption of NMA is the consistency of direct and indirect evidence. Consistency equations were first set
Abbreviations: NMA, network meta-analysis; RCTs, randomized controlled trials; Seq CT, sequential chemotherapy, Con CT, concomitant
chemotherapy; Dir, direct; Ind, indirect; Net, network; RT, radiotherapy; IPD, individual participant data.
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out by Higgins and Whitehead1 who showed that the relative effects of different treatments could be jointly estimated by
“borrowing strength” from direct comparisons to inform indirect comparisons. Inconsistency in NMA occurs when the
direct and indirect evidence are not in agreement with each other. This can result in biased treatment effect estimates.
Inconsistencywithin a networkmay arisewhen bias in direct comparisons (for example optimismbias, publication bias or
sponsorship bias) acts differently in different comparisons or when treatment effect modifiers are distributed differently
in different comparisons.2,3 The power of tests for inconsistency is generally low because indirect evidence is typically a
relatively weak component of most treatment estimates in NMA. Failure to reject the null hypothesis of no inconsistency
does notmean that the entire network is consistent.4 Nevertheless,the increasing use of NMA in health decisionmodeling
means that it is important that attempts aremade to identify, understand, andwhere appropriate, adjust for inconsistency.
As is typical in the NMA literature, throughout this paper, “design” will refer to the treatments being compared within
a trial.5 For example, two trials both comparing treatment A to treatment B will be considered to be of the same design,
whereas a third trial comparing treatment A to treatment B and treatment C will be considered to be of a different design.
For a full review of NMAmethods, see Salanti6 and Efthimiou et al.7
There are several approaches for assessing inconsistency in a network; in particular, we take a closer look at Cochran's
Q statistic,8 the loop inconsistency approach,9 the inconsistency parameter approach,10 node-splitting,11 and the net heat
approach.12 Between them, these fivemethods offer a range of increasingly complexmethods for identifying inconsistency
in a network. Cochran's Q statistic8 and the loop inconsistency approach of Bucher9 are relatively simple methods that
aim to identify inconsistency through one test statistic and a p-value. Both the inconsistency parameter approach of Lu
and Ades10 and node-splitting11 allow for inconsistency in a Bayesian hierarchical model, which allows the amount of
inconsistency to be quantified and a credible interval calculated. Krahn et al12 also use a modeling approach; however,
the results are displayed graphically as a net heat plot, with the aim of allowing inconsistency to be identified, and are not
linked to a statisticaltest.
Cochran's Q statistic8 is a common method for assessing heterogeneity in a meta-analysis. The generalized Cochran's
Q statistic for multivariate meta-analyses13 can be used in the context of NMA to quantify heterogeneity across the whole
network, both within trial designs and between trial designs (the latter is known as inconsistency).
Bucher9 developed a method for assessing loop inconsistency in loops of three treatments within a network consisting
of two-arm trials only. The approach involves calculating the difference between the direct and indirect evidence for a
treatment comparison and testing it against the null hypothesis of consistency by referring the test statistic to the normal
distribution. However, in a large network where each treatment loop is considered one at a time, multiple testing must
be taken into account, and this approach can be both cumbersome and time consuming.14,15
One of the most popular models to account for inconsistency in a network is the Bayesian hierarchical model of Lu
and Ades.10 This model is a generalization of the Bucher approach and relaxes the consistency assumption by including
an inconsistency parameter in each loop in which inconsistency could occur. These additional inconsistency parameters
can be fitted as fixed or random effects. Models with and without inconsistency parameters are then compared to assess
whether a network is consistent and the analyst must make an arbitrary choice about this. However, in the presence of
multi-arm trials, this approach depends on the order of treatments.
Cochran's Q statistic,8 the loop inconsistency approach,9 and the inconsistency parameter approach10 all pro-
vide a global assessment of inconsistency in a network; however, local methods for assessing inconsistency are also
needed in order to identify which treatment comparisons are driving the inconsistency.11 Dias et al11 first proposed
comparison-specific assessment of inconsistency using node-splitting. Node-splitting involves separating out the evi-
dence for a particular treatment comparison into the direct and indirect evidence and assessing the discrepancy between
them, one treatment comparison at a time.11 Node-splitting can be considered equivalent to the inconsistency parame-
ter approach of Lu and Ades if all the treatment nodes are split at the same time so that separate treatment effects are
estimated for each treatment comparison without assuming consistency over any set of trials.11
To aid the identification of inconsistency within a network, Krahn et al12 developed a method, known as the net heat
plot, which could be used as a visual aid for locating and identifying any inconsistency within a network of randomized
controlled trials (RCTs). The net heat plot uses Cochran's Q statistic in a fixed effect framework and decomposes it into
within-trial heterogeneity and inconsistency. The net heat plot is constructed by temporarily removing each design one at
a time and assessing the contribution of each design to the inconsistency of thewhole network. The difference between the
inconsistency in the network before the temporary removal of each design and the inconsistency that remains following
the temporary removal of each design, known as Qdiff, is displayed graphically in the form of a matrix. The net heat plot
is then colored so that the coloring of each square indicates designs which increase or decrease inconsistency within the
network.
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Cochran's Q statistic, the loop inconsistency approach, the inconsistency parameter approach, and node-splitting all
use formal statistical tests to draw conclusions about possible inconsistency in a network. In contrast,Qdiff (the difference
between two Q statistics, which themselves follow chi-squared distributions) has a nonstandard distribution and is there-
fore much harder to interpret. The coloring of the net heat plot is driven by Qdiff, and it is unclear what value of Qdiff
constitutes statistically significant or clinically meaningful inconsistency.
In this paper, we take a closer look at the net heat plot and highlight some previously unremarked limitations of this
approach. In Section 2, we introduce two networks of trials in lung cancer and diabetes and assess the possibility of incon-
sistency using a visual approach. In Section 3, we consider five methods for assessing inconsistency in NMA: Cochran's
Q statistic,8 the loop inconsistency approach,9 the inconsistency parameter approach,10 node-splitting,11 and the net heat
plot.12 In Section 4, we derive algebraic expressions for the elements of the net heat plot in terms of direct treatment esti-
mates and interpret them with the aid of numerical simulations in Section 5. In Section 6, we apply the five methods of
assessing inconsistency to the lung cancer and diabetes networks before offering a conceptual critique in Section 7. In
Section 8, we finish with a discussion.
2 DATASETS
In this section, we introduce two datasets to which we will apply methods for assessing inconsistency in NMA. We first
introduce a simple three-treatment network for lung cancer (to illustrate the underlying arguments) and secondly a more
complex network of 10 treatments for diabetes.
2.1 Lung cancer network
For our first network, we consider the simplest network structure possible: one treatment loop consisting of three
treatments without multiarm trials. The data for this network come from three meta-analyses of RCTs in lung cancer per-
formed by the Non-Small-Cell Lung Cancer Collaborative Group. These data were obtained from Gustave-Roussy (GR),
Paris. The three meta-analyses considered three different treatments: radiotherapy (RT), radiotherapy plus sequential
chemotherapy (Seq CT), and radiotherapy plus concomitant chemotherapy (Con CT) using three different designs: RT v
Seq CT, RT v Con CT, and Seq CT v Con CT (Figure 1).
The meta-analysis (MA) of RT and Seq CT was published in 1995 and included 3033 patients from 22 RCTs.16 The cur-
rent dataset was updated by GR to include some newer trials and exclude some trials using older forms of chemotherapy.
This comparison now includes a total of 21 RCTs and 3387 patients. TheMA of RT and Con CTwas published in the work
of Auperin et al17 and included 1764 patients from 9 RCTs. This MA was also updated by GR to include a total of 16 trials
and 2969 patients. The MA of Seq CT and Con CT was published in 2010 and included 6 RCTs and 1205 patients.18 One
multiarm trial (45 patients) comparing all three treatments was excluded from the network for the analyses in this paper
in order to obtain the simplest network structure possible for a network meta-analysis. In total, overall survival data was
available for 7531 patients from 42 RCTs. A list of all RCTs is provided in Appendix A (supplementary material).
The lung cancer network forms one treatment loop, so there can only be one inconsistency source. It provides a sim-
ple yet revealing starting point for assessing the net heat plot. To visually assess the agreement between the direct and
indirect evidence within the lung cancer network, before any formal statistical models were fitted, the treatment effects
for all pairwise comparisons were estimated in a number of ways. Network estimates combining both direct and indirect
FIGURE 1 Lung cancer network diagram. The node size is weighted
according to the number of patients randomized to each treatment, and the
line thickness is weighted according to the number of studies involved in
each direct comparison. Key to treatments: Con CT, radiotherapy plus
concomitant chemotherapy; Pts, patients;RCTs, randomized clinical trials;
RT, radiotherapy; Seq CT, radiotherapy plus sequential chemotherapy
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FIGURE 2 Forest plot of various analyses
of the lung cancer data. All models were
fitted with fixed effects. Key to treatments:
Con CT, concomitant chemotherapy; CrI,
credible interval (except netmeta models
where confidence intervals are presented);
IP, inconsistency parameter; NMA, network
meta-analysis; RT, radiotherapy; Seq CT,
sequential chemotherapy
treatment effects were obtained by fitting a one-step IPD NMA Royston-Parmar model for time-to-event data19,20 using
a Bayesian approach and by fitting a two-step NMA using the R package netmeta.21 An estimate of the direct evidence
was obtained by fitting the one-step IPD Royston-Parmar MA model to trials directly comparing the treatments of inter-
est only. Indirect treatment effects were also calculated using the one-step IPD Royston-Parmar MA model, where all
trials directly comparing the two treatments of interest were excluded from the model. Throughout this paper, all models
are fitted with fixed effects assuming no heterogeneity in any of the direct comparisons to simplify calculations in later
sections of the paper. In the Bayesian estimation of the Royston-Parmar model, parameters representing the spline func-
tion for the baseline log cumulative hazard function and treatment effects were fitted with noninformative normal prior
distributions.
Figure 2 presents the forest plot of treatment effects for each pairwise comparison, using the methods described above
and including the results of the inconsistency parameter approach, described below in Section 3.3. The forest plot clearly
shows a difference between the direct and indirect evidence for each pairwise comparison.
2.2 Diabetes network
For our second network, we consider a more complex network structure consisting of multiple treatments and mul-
tiarm trials. The network considers 10 treatments for type 2 diabetes: acarbose (acar), benfluorex (benf), metformin
(metf), miglitol (migl), pioglitazone (piog), placebo (plac), rosiglitazone (rosi), sitagliptin (sita), sulfonylurea alone (sual),
vildaglitin (vild) using 15 different designs: metf v plac, acar v metf v plac, piog v plac, metf v piog, piog v rosi, metf v rosi,
rosi v sual, acar v sual, acar v plac, plac v vild, metf v sual, migl v plac, metf v rosi, migl v rosi, benf v plac (Figure 3). The
data for this network were initially collected and reported by Senn et al.22 In total, glycated haemoglobin (HbA1c) data
were available for 6646 patients from 26RCTs.
The diabetes network contains multiple treatment loops and provides a more challenging example for assessing incon-
sistency. To visually assess the agreement between the direct and indirect evidence within the diabetes network, we
fitted a two-step NMA using the R package netmeta21 and obtained estimates of the direct and indirect evidence from
node-splitting.
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FIGURE 3 Diabetes network diagram. The line thickness is proportional to the
number of studies involved in each comparison. Multiarm trial includes placebo,
metformin and acarbose. Key to treatments: acar, acarbose; benf, benfluorex; metf,
metformin; migl, miglitol; piog, pioglitazone; plac, placebo; rosi, rosiglitazone; sita,
sitagliptin; sulf, sulfonylurea; vild, vildagliptin
Figure S1 (supplementarymaterial) presents the forest plot of treatment effects for each pairwise comparison. The forest
plot clearly shows a difference between the direct and indirect evidence for the pairwise comparisons of metf v sulf and
rosi vsulf.
3 METHODS FOR ASSESSING INCONSISTENCY IN NMA
In this section, we describe five methods for assessing inconsistency inNMA.
3.1 Cochran's Q statistic
Cochran's Q statistic can be used to assess heterogeneity within a network. The overall Q statistic from the fixed effect
NMA model can be decomposed into within-design heterogeneity (Qhet) and between-design heterogeneity, which is
termed design inconsistency (Qinc). Let ?̂?ic be the treatment effect estimate from trial i for the comparison of treatments
in design cwith corresponding standard error ?̂?ic, where there are 1, … ,nc trials of design c. Let ?̂?c be the treatment effect
from the direct evidence for design c only with corresponding standard error ?̂?c and ?̂?Nc be the network estimate of the
treatment effect for design c; then,
Q =
∑
c
nc∑
i=1
{
?̂?ic − ?̂?Nc
?̂?ic
}2
Qhet =
∑
c
nc∑
i=1
{
?̂?ic − ?̂?c
?̂?ic
}2
Qinc =
∑
c
{
?̂?c − ?̂?Nc
?̂?c
}2
,
with Q = Qhet + Qinc.
For multiarm studies, ?̂?ic is a vector with variance Sic, and these formulae are extended to
∑
c
∑
i(?̂?ic − ?̂?Nc)TS−1ic (?̂?ic− ?̂?Nc),
etc.13
3.2 Loop inconsistency
From now on, throughout this paper, we use the shorthand dir to represent direct evidence, ind to represent indirect
evidence and net to represent network evidence (ie, the combination of the direct and indirect evidence). In a loop of
three treatments A, B, and C, we compared the direct evidence of treatment C versus treatment A, ?̂?dirAC, to the indirect
evidence, ?̂?indAC , where ?̂?
ind
AC = ?̂?
dir
AB + ?̂?
dir
BC and Var(?̂?
ind
AC ) = Var(?̂?
dir
AB) + Var(?̂?
dir
BC). Following the method of Bucher,
9 estimates
of the inconsistency parameter, ?̂?AC, and its variance can be formed, within a loop, by subtracting the direct and indirect
estimates
?̂?AC = ?̂?dirAC − ?̂?
ind
AC (1)
Var(?̂?AC) = Var
(
?̂?dirAC
)
+ Var
(
?̂?indAC
)
= Var
(
?̂?dirAC
)
+ Var
(
?̂?dirAB
)
+ Var
(
?̂?dirBC
)
.
An approximate test of the null hypothesis of consistency is conducted by referring the test statistic zAC = ?̂?AC√Var(?̂?AC) to the
normal distribution.
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3.3 Inconsistency parameter approach
The inconsistency parameter approach of Lu and Ades10 involves adding an extra parameter (the inconsistency parame-
ter) to each treatment loop within a network to assess inconsistency and estimate both the direct and indirect evidence
simultaneously. This allows estimates of the direct and indirect information to be obtained for each comparison within
the treatment loop. In a network containing one three-treatment loop between treatments A, B, and C, let 𝜔ABC represent
the inconsistency parameter for this loop. For example, under the Royston-Parmarmodel for time-to-event outcomes, the
log cumulative hazard for patient i in trial j is given by
ln{Hi𝑗(t|xi𝑗)} = s𝑗 (ln(t)) + 𝛽1trt1i𝑗 + 𝛽2trt2i𝑗 − 𝜔ABCtrt1i𝑗trt2i𝑗 , (2)
where s𝑗(ln(t)) is the restricted cubic spline modeling the baseline log cumulative hazard for trial j, trt1ij and trt2ij are
treatment indicator variables, and 𝛽1 and 𝛽2 are the treatment effect estimates for trt1ij and trt2ij compared to the reference
treatment, respectively.
3.4 Node-splitting
Node-splitting compares a model where the consistency assumption is relaxed for one treatment comparison to the
model assuming consistency across the entire network to highlight inconsistent treatment comparisons within the net-
work. Each treatment comparison is considered separately and one at a time for evidence of possible inconsistency.
Node-splitting can be implemented using the “network sidesplit all” command23 in Stata,24 which reports the treatment
effects from the direct and indirect evidence together with their difference and a test of whether the true difference is
equal to zero for each treatment comparison.23
3.5 Net heat plot
In 2013, Krahn et al12 introduced the net heat plot as amethod for identifying and locating inconsistencywithin a network
of RCTs. In a network of RCTs with at least one treatment loop, the net heat plot is constructed by temporarily removing
(also referred to as detaching) each design one at a time and assessing the contribution of each design to the inconsistency
of the whole network.
Krahn et al12 propose the use of a design-by-treatment interaction approach, whereby the consistency assumption for
one of the treatment loops is relaxed so that the remaining inconsistency across the network can be calculated. In practice,
this is computationally simple because it is equivalent to a “leave one out” approach in which Qinc is simply recalculated
from scratch after the (temporary) removal of each design in turn (which is equivalent to removing each loop in turn,
assuming each design features in only one loop). Designs that do not contribute to a treatment loop or when removed
would split the network into two distinct parts are excluded from the net heatplot.
In an NMA model, the design matrix contains the structure of the network at the study level and links the observed
treatment effects with the treatment contrast parameters. To detach design d, we add to the design matrix additional
columns. The number of columns to add is equal to the number of treatments in design dminus 1. Thus, when design d
includes two treatments, one column is added, consisting of a “1” in the row corresponding to the design, which is being
detached and “0” elsewhere (this is analogous to perfectly fitting an observation in a regression by including a dummy
variable for just that observation). The treatment effects for each comparison in the network are then recalculated using
this new design matrix, and the inconsistency in the network when design d is detached is thus calculated.
The between-design inconsistency statistic,Qinc, is the part of the total heterogeneity in the network that is not explained
by heterogeneity within designs. Let Qincc represent the inconsistency in the network for design c before any designs are
detached, where Qinc = ∑cQincc = ∑c(?̂?dirc − Xc?̂?net)′Var(?̂?dirc )−1(?̂?dirc − Xc?̂?net), where Xc is the design matrix and ?̂?net is the
vector of treatment parameter estimates. LetQincc(d) represent the inconsistency remaining in the network for design cwhen
design d is detached and Qdiffc,d denote the change in inconsistency for design c resulting from detaching design d. Then,
Qdiffc,d = Q
inc
c − Qincc(d).
The values of Qdiffc,d form the basis of the net heat plot. The net heat plot is constructed as a matrix in which each
off-diagonal square is Qdiffc,d , representing the contribution of the row design (c) to the total inconsistency across the net-
work when the column design (d) is detached (ie, the consistency assumption is relaxed for the column design). The
leading diagonal, running from the top left to the bottom right corner, displays the contribution of each design c, Qincc , to
the between design statistic, Qinc.
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Moreover, in each net heat plot, the area of the grey squares within each matrix cell are proportional to the absolute
values of the hatmatrix (of theNMA regressionmodelwith no designs detached). These are interpretable as the (statistical
information) contribution of the direct estimate of the column design to the network estimate of the row design. As
proposed by Krahn et al, the net heat plot is colored so that values of Qdiffc,d > 0 take on yellow and red colors and values
of Qdiffc,d < 0 take on white and blue colors. The coloring varies in intensity with the maximum intensity (ie, the brightest
colors) representing absolute values of Qdiffc,d greater than or equal to eight. Red colors indicate that the contribution of
the evidence from the column design toward the row design is inconsistent with the other evidence in the network. Blue
colors indicate that the contribution of the evidence from the column design toward the row design is consistent with the
other evidence in the network.25 This enables the reader to identify which designs are most likely to be responsible for
the inconsistency in the network.
Net heat plots can be produced with the package netmeta21 in R.26
4 A CLOSER LOOK AT THE NET HEAT PLOT
As NMA is a form of regression, we would expect any diagnostic useful in the NMA case to be meaningful in simpler
cases. We now look in more detail at the calculation underlying the net heat plot starting in Section 4.1 by considering a
three-treatment network before generalizing the result and exploring the interpretation in Section 4.2.
4.1 Three-treatment network
We consider a three-treatment network, consisting of treatments A, B, and C, in which direct evidence is available for all
pairwise comparisons. In this setting, we consider two-arm trials only. The aim here is to look at what happens to the
inconsistency for design c when we detach design d. There are two possible scenarios: d ≠ c and d = c.
In a network of three treatments, there is only one pathway of indirect evidence. For example, for the comparison
AC, the pathway of indirect evidence goes via treatment B. We denote the direct treatment effect by ?̂?dirc and the indirect
treatment effect by ?̂?indc . Applying these definitions to a three-treatment network, consisting of treatments A, B, and C
and letting c = AC, we have
?̂?dirc = ?̂?dirAC, with variance s
2
AC,
?̂?indc = ?̂?dirAB + ?̂?
dir
BC, with variance s
2
AB + s
2
BC.
The network estimate is equal to the inverse variance weighted average of all the direct and indirect evidence combined
?̂?netAC =
s2AB + s
2
BC
s2AC + s
2
AB + s
2
BC
?̂?dirAC +
s2AC
s2AC + s
2
AB + s
2
BC
?̂?indAC .
For design c, the inconsistency Q statistics are defined as
Qincc =
1
s2c
(
?̂?dirc − ?̂?netc
)2 (3)
Qincc(d) =
1
s2c
(
?̂?dirc − ?̂?netc(d)
)2
, (4)
where s2c = Var(?̂?dirc ).
Qincc represents the difference between the direct and network evidence for design c across the whole network.
Continuing with c = AC, we have
QincAC =
1
s2AC
(
?̂?dirAC − ?̂?
net
AC
)2 = 1
s2AC
[
s2AC
s2AC + s
2
AB + s
2
BC
(
?̂?dirAC − ?̂?
ind
AC
)]2
.
Qincc(d) represents the difference between the direct and network evidence for design c when design d is detached, and
Qdiffc,d represents the change in inconsistency for design c when design d is excluded from the network so that
QdiffAC,d = Q
inc
AC − Q
inc
AC(d). (5)
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When d ≠ c, the pathway of indirect evidence must include design d. Therefore, the network estimate of design cwhen
design d is detached is
?̂?netAC(d) = ?̂?
dir
AC.
In this setting, QincAC(d) = 0. Therefore, (5) can be rewritten as
QdiffAC,d =
1
s2AC
(
?̂?dirAC − ?̂?
net
AC
)2 = 1
s2AC
[
s2AC
s2AC + s
2
AB + s
2
BC
(
?̂?dirAC − ?̂?
ind
AC
)]2
. (6)
When d = c, the network estimate for design c, when the direct evidence for design c is excluded, is equal to the indirect
evidence for design c
?̂?netAC(c) = ?̂?
ind
AC .
Therefore, Qdiffc,c is calculated as
QdiffAC,AC = Q
inc
AC − Q
inc
AC(AC) =
1
s2AC
⎡⎢⎢⎣
(
?̂?dirAC − ?̂?
ind
AC
)2 ⎛⎜⎜⎝
(
s2AC
s2AC + s
2
AB + s
2
BC
)2
− 1
⎞⎟⎟⎠
⎤⎥⎥⎦ . (7)
In both cases, (6) and (7) are scaled and squared versions of the inconsistency parameter (1). Thus, the net heat statistics
are correlated with the formal inconsistency test statistic in this setting, in this example. However, these scaled versions of
the inconsistency parameter have scaled chi-squared distributions, making them awkward to interpret; why scale when
the unscaled version has a known distribution?
4.2 Generalizing the net heat plot to a network with k+2 treatments where direct
evidence is limited to specific comparisons
In this section, we use a more general network to illustrate the mathematics behind the net heat plot. We assume a
network of two-arm trials consisting of treatments A and B and additional treatments X1,X2, … ,Xk. In this network,
there is only direct evidence comparing A versus B, A versus X1,X2, … ,Xk and B versus X1,X2, … ,Xk. There are no trials
directly comparing Xi and Xj. We make the same assumptions as before: each trial has the same number of patients and
each comparison has the same number of trials. Here, for simplicity, we assume the variance of the treatment effect, s2,
is common to all designs. We assume an equal weight of 1s2 for each of the direct comparisons in the network so that each
indirect comparison has weight 12s2 . We let c be the design of interest (eg, A versus B), with direct estimate ?̂?
dir
c . There are
k possible indirect pathways, each involving a single additional node. Each additional node adds one loop to the network.
Therefore, there are a total of k + 2 treatments relevant to design c. Denote the indirect estimates by ?̂?ind(i)c , i = 1, … , k.
The network estimate of c is equal to the weighted average of all the direct and indirect evidence combined, that is,
?̂?netc =
1
k + 2
{
2?̂?dirc +
k∑
i=1
?̂?
ind(i)
c
}
.
To test the effect of detaching design d, there are two scenarios: d ≠ c and d = c. Assume first that d ≠ c and let the
effect size for design d be ?̂?ind(d)c . Then, when design d is detached, the remaining network evidence on c is
?̂?netc(d) =
1
k + 1
{
2?̂?dirc +
∑
i,i≠d
?̂?
ind(i)
c
}
.
If, instead, the direct comparison, d = c, is detached, the network evidence remaining for design c is
?̂?netc(c) =
1
k
k∑
i=1
?̂?
ind(i)
c .
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We now define ?̂?netc(d∕2) as the average of all the network evidence for design c and the network evidence that remains for
design c when design d is excluded so that
?̂?netc(d∕2) =
1
2
(
?̂?netc(d) + ?̂?
net
c
)
.
Wewrite the difference between the network evidence on cwhen d is excluded and the network evidence on c in terms
of ?̂?ind(i)c and putting it all together
Qdiffc,d =
2
s2
(
?̂?netc(d) − ?̂?
net
c
) [
?̂?dirc −
1
2
(
?̂?netc(d) + ?̂?
net
c
)]
= 1
s2
× 1k + 2
{
1
k + 1
(
2?̂?dirc +
∑
i,i≠d
?̂?
ind(i)
c
)
− ?̂?ind(d)c
}
×
[
2?̂?dirc
(
1 − 2k + 3
(k + 1)(k + 2)
)
− 1k + 2
(
2k + 3
k + 1
∑
i,i≠d
?̂?
ind(i)
c + ?̂?
ind(d)
c
)]
. (8)
Else, if the direct comparison is detached,
Qdiffc,c = −
1
s2
× 4(k + 1)
(k + 2)2
(
?̂?dirc −
1
k
k∑
i=1
?̂?
ind(i)
c
)2
.
For k = 1, the three-treatment case, we obtain (6) and (7).
Suppose k is large so that k + 1 ≈ k; then, we can approximate (8) by
Qdiffc,d ≈
1
s2
{
1
k
(
2?̂?dirc +
∑
i,i≠d
?̂?
ind(i)
c
)
− ?̂?ind(d)c
}
×
[
1
k
{
2?̂?dirc −
2
k
∑
i,i≠d
?̂?
ind(i)
c −
1
k ?̂?
ind(d)
c
}]
. (9)
Essentially, (9) is a scaled product of two terms
Qdiffc,d ≈
1
s2
P1P2,
where
P1 ≈
1
k
(
2?̂?dirc +
∑
i,i≠d
?̂?
ind(i)
c
)
− ?̂?ind(d)c
and
P2 ≈
1
k
{(
?̂?dirc − ?̂?indc
)
+
(
?̂?dirc −
1
k
∑
i,i≠d
?̂?
ind(i)
c
)}
.
Let ?̂?ind(−d)c = average(
∑
i,i≠d?̂?
ind(i)
c ); then, if k is large, we can simplify further
P1 ≈ ?̂?ind(−d)c − ?̂?
ind(d)
c
P2 ≈
2
k
(
?̂?dirc − ?̂?indc
)
.
Full details can be found in Appendix B (supplementary material).
Term P1 is the difference between the average indirect estimate for design c excluding design d and the indirect evidence
for design c “from design d.”While the square of this is a plausiblemeasure of the difference between the evidence coming
from the loop including design d and the rest of the network (excluding the direct evidence), it is not specific to design d
but to the loop including design d.
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Term P2 is a scaled difference between the direct evidence for design c and the indirect evidence for design c. Term P2
can be large if the direct and indirect evidence differ and small if the direct and indirect evidence are similar. Therefore,
in some cases, it could be a poor choice of multiplier for term P1.
We conclude that the terms used in the net heat plot neither generally identify designs causing inconsistency nor are
necessarily relatively large if inconsistency is present (as P2 may be small).
5 SIMULATION STUDY: WHAT HAPPENS AS WE INCREASE THE NUMBER
OF TREATMENT LOOPS IN A NETWORK?
In Section 4.2, we used equal variances to simplify calculations. However, this is unlikely to be realistic in most NMA
cases. We now address this by using simulation to investigate what happens when we have the situation described in
Section 4.2 where P1 is large, P2 is small, andwe have unequal variances: our aim is to demonstrate that P2 is a poor choice
of multiplier for P1. In more detail, the aim of this simulation study is to show, in a network in which we know there is
inconsistency, that as the network increases in size, the ability of the net heat approach to identify this inconsistency is
diminished.
We consider a network consisting of one treatment loop in which all the treatment effects are the same. We then inflate
the treatment effect in one design to introduce inconsistency into the network. Treatment loops are added one at a time
to the network and the values of Qdiffc,d , Q
inc
c , and Qincc(d) are monitored. As above, Q
inc
c quantifies the total amount of incon-
sistency for design c before detachment of design d. Qincc(d) quantifies the total amount of inconsistency for design c after
detachment of design d. Qdiffc,d quantifies the reduction in inconsistency for design c following the detachment of design d.
Specifically, we start with a network consisting of one treatment loop (A,B,C). For each design, we simulate six trials.
We generate the true treatment effects for each trial from designs AB and BC from a normal distribution with mean 0 and
standard deviation 0.2. We generate the true treatment effect for the design AC for each trial from a normal distribution
with mean 2 and standard deviation 0.2. This has the effect of introducing inconsistency between the direct and indirect
evidence for the AC comparison. For each simulated trial treatment estimate, a corresponding standard error estimate is
simulated from the normal distribution for the treatment effect with mean 0 and standard deviation 1. This ensures the
standard error estimates are positive. As we move through the sequence of networks, each time we resimulate, the true
treatment effects from these distributions. We repeat this process, adding one treatment at a time. At each stage, we have
a network of two-arm trials consisting of treatmentsA and B and additional treatments X1,X2, … ,Xk. There is only direct
evidence comparingA versus B,A versus X1,X2, … ,Xk and B versus X1,X2, … ,Xk. There are no trials directly comparing
Xi and Xj. We stopped when we reached 10 treatment loops. Qdiffc,d , Q
inc
c , and Qincc(d) are calculated with c = AB and d = AC.
R code can be found in Appendix D (supplementary material).
In this situation, we know that before detachment of designs, inconsistency will be present between the direct and
indirect estimates for the design AB because the indirect estimate for AB includes the inflated estimate of AC. Detaching
design ACwill then remove the inconsistency in the network, which will be quantified byQdiffc,d . Figure 4 plotsQ
diff
c,d against
the number of treatment loops in the network. Estimates ofQdiffc,d ,Q
inc
c , andQincc(d) are presented in Table S1 (supplementary
material).
In terms of the notation used in Section 4.2, we expect to see that as we increase the number of treatment loops in the
network, P1 remains the same, but P2 is reduced because adding more indirect evidence to the calculation of 𝜃indc “waters
down” the direct evidence coming from design d and thus masking the inconsistency in the network, which shows that
P2 is a poor choice of multiplier for P1.
Figure 4 and Table S1 (supplementary material) confirm this, showing that inconsistency due to design d in the net
heat plot diminishes as the number of treatment loops increases but the amount of inconsistency in loop ABC remains
the same. Therefore, as we increase the size of the network, the effect of inconsistency in one design is reduced so that in
a network with a large number of loops, inconsistency will be hidden, ie, as we increase the amount of direct evidence on
design c, the inconsistency in design d is masked. The net heat plot highlights concerns about inconsistency in a network
when Qdiffc,d > 8. In this example, concerns about inconsistency are masked once there are seven or more treatment loops.
Inconsistency is a property of loops and as such the loop-specific approaches considered in Sections 3.1, 3.2 and 3.3 are
not affected by increasing the number of treatment loops in a network. However, node-splitting models which compare
the direct and indirect evidence for a comparisonmay be affected by increasing the number of consistent treatment loops.
Therefore, we applied the node-splitting approach to the same 10 simulated datasets. As expected, increasing the number
of consistent treatment loops in the network (ABX1,ABX2, … ) increased the sources of indirect evidence and reduced the
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effect of the indirect evidence from the ABC loop. The key differences between the net heat plot and the node-splitting
approach are that (1) the net heat plot multiplies P1 and P2 while claiming to identify when P1 is large (irrespective of P2)
and (2) the node-splitting approach gives a statistically valid estimate of P2 and test of the null hypothesis that it is zero.
6 APPLICATION OF METHODS FOR ASSESSING INCONSISTENCY
In this section,we apply the fivemethods for assessing inconsistency described in Section 3 to the lung cancer and diabetes
networks.
6.1 Lung cancer network
We now apply the methods described in Section 3 to the lung cancer network introduced in Section 2.1. Cochran's Q
statistic showed evidence of statistically significant heterogeneity in the whole network (Q = 56.59, 40 df, p=0.043) and
inconsistency between designs (Qinc = 4.52, 1 df, p=0.034. Heterogeneity within designs was close to the threshold of
0.05 but did not reach statistical significance (Qhet = 52.07, 39 df, p=0.079). In the lung cancer network where there are
no multi-arm trials the loop inconsistency approach and Cochran's Q statistic are algebraically equivalent and therefore
provide the same level of evidence for inconsistency in the lung cancer network. Letting A = RT, B = Seq CT, and C =
Con CT, we have
?̂?dirAB = −0.132,Var
(
?̂?dirAB
)
= 0.0362
?̂?dirAC = −0.138,Var
(
?̂?dirAC
)
= 0.0392
?̂?dirBC = −0.179,Var
(
?̂?dirBC
)
= 0.0622
?̂?indAC = −0.132 + (−0.179) = −0.311,Var
(
?̂?indAC
)
= 0.0362 + 0.0622 = 0.0722
?̂?AC = −0.138 − (−0.311) = 0.173,Var(?̂?AC) = 0.0392 + 0.0362 + 0.0622 = 0.0822
zAC =
0.173
0.082 = 2.11, p = 0.035.
To assess inconsistency and estimate both the direct and indirect evidence simultaneously, we conducted a NMA using
the Royston-Parmar time-to-event model, including a fixed effect inconsistency parameter following the method of Lu
and Ades.10 The inconsistency parameter was fitted with a noninformative normal prior distribution. The inconsistency
parameter was estimated as −0.176 (95% Credible Interval: −0.337, −0.016), giving an approximate p-value of 0.032 and
suggesting evidence of network inconsistency.Node-splitting also resulted in p=0.033 for the difference between the direct
and indirect evidence for each treatment comparison (Table 1).
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TABLE 1 Node-splitting results for the
lung cancer network
Direct Indirect Difference
Comparison Coef. Std. Err. Coef. Std. Err. Cef. Std. Err. P-value
RT v Seq CT 0.131 0.036 0.043 0.074 −0.175 0.082 0.033
RT v Con CT 0.134 0.40 −0.309 0.072 0.175 0.082 0.033
Seq CT v Con CT −0.177 0.063 −0.002 0.054 −0.175 0.082 0.033
Abbreviations: Con CT, radiotherapy plus concomitant chemotherapy; RT, radiotherapy; Seq CT, radiother-
apy plus sequential chemotherapy.
FIGURE 5 Net heat plot for the lung cancer network. Key to
treatments: RT, radiotherapy; SeqCT, sequential chemotherapy;
ConCT, concomitant chemotherapy [Colour figure can be viewed at
wileyonlinelibrary.com]
The net heat plot is presented in Figure 5. The yellow colors indicate Qdiffc,d > 0. However, there are no areas of vibrant
red, so it may be reasonable to conclude that there is no meaningful inconsistency in the lung cancer network, in contrast
to the methods above. The difference in the shades of yellow suggests that inconsistency is most important in the Seq CT
v Con CT treatment comparison. However, the Seq CT v Con CT comparison has the least amount of direct evidence, and
therefore, the decomposition of Q has attributed the inconsistency mainly to this comparison.
To explore (6) further, we now calculate Qdiffc,d . If we let c =AC be the comparison of interest, then ?̂?
dir
AB, ?̂?
dir
AC, ?̂?
dir
BC, and ?̂?
ind
AC
are as defined in Section 3.2. The network evidence for AC can be calculated as follows:
?̂?netAC =
0.0362 + 0.0622
0.0392 + 0.0262 + 0.0622
(−0.138) + 0.039
2
0.0392 + 0.0362 + 0.0622
(−0.132 + −0.179) = −0.1776
The Q statistics can be calculated from (3), (4), and (5) as follows:
QincAC =
1
s2AC
(
?̂?dirAC − ?̂?
net
AC
)2 = 1
0.0392 (
−0.138 − −0.1776)2 = 1.026
QincAC(d) =
1
s2AC
(?̂?dirAC − ?̂?
net
AC(d))
2 = 1
0.0392 (
−0.138 − −0.138)2 = 0
QdiffAC,d = Q
inc
AC − Q
inc
AC(d) = 1.026,
which gives the same result as (6), indicating negligible inconsistency, in contrast, to a formal statistical test which rejects
the null hypothesis with p=0.03.
6.2 Diabetes network
We now apply the methods described in Section 3 to the diabetes network introduced in Section 2.2. Cochran's Q statis-
tic showed evidence of statistically significant inconsistency between designs (Qinc = 22.53, 7df, p=0.002) and within
designs (Qhet = 74.46, 11df, p<0.001). The net heat plot (Figure 6) raises concerns about inconsistency (Qdiffc,d > 8)
within the metformin (metf), sulfonylurea (sulf), and rosiglitazone (rosi) treatment loop and particularly the compar-
isons involving sulfonylurea. However, the loop inconsistency and node-splitting approaches are able to formally test this.
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FIGURE 6 Net heat plot for the diabetes
network. Key to treatments: acar, acarbose;
benf, benfluorex; metf, metformin; migl,
miglitol; piog, pioglitazone; plac, placebo;
rosi, rosiglitazone; sita, sitagliptin; sulf,
sulfonylurea; vild, vildagliptin [Colour
figure can be viewed at
wileyonlinelibrary.com]
Letting A = metformin, B = sulfonylurea, and C = rosiglitazone, for the diabetes network and following the loop
inconsistency approach outlined in Section 3.2, we have
?̂?dirAB = −0.370,Var
(
?̂?dirAB
)
= 0.014
?̂?dirAC = 0.073,Var
(
?̂?dirAC
)
= 0.026
?̂?dirBC = 1.20,Var
(
?̂?dirBC
)
= 0.021
?̂?indBC = 0.073 − (−0.370) = 0.443,Var
(
?̂?indAC
)
= 0.026 + 0.014 = 0.040
?̂?BC = 1.20 − 0.443 = 0.757,Var(?̂?AC) = 0.021 + 0.026 + 0.014 = 0.061
zBC =
0.757√
0.061
= 3.07, p = 0.002.
The results of node-splitting in the diabetes network are presented in Table S2 (supplementary material). For the sul-
fonylurea and rosiglitazone and sufonylurea and metformin comparisons, p<0.001, suggesting evidence of important
inconsistency within the diabetes network.
We have not applied the inconsistency parameter approach to the diabetes network. In a large network such as the
diabetes network, it is computationally simpler to use the node-splitting approach instead.
In this example, the net heat plot is in agreement with the loop inconsistency and node-splitting approaches with
all three identifying important inconsistency within the metformin, sulfonylurea, and rosiglitazone treatment loop. All
three approaches also identified the treatment loop metformin, pioglitazone (piog), and placebo (plac) as an area of con-
cern. The net heat plot colors this treatment loop yellow (Qdiffc,d ≈ 4), suggesting that although inconsistency may be
present, it is not important. The loop inconsistency approach is able to formally test this and reaches a similar conclusion
(z=1.80, p=0.073). The node-splitting approach also suggests evidence of important inconsistency in the network (Table
S2, supplementary material).
In this example, the net heat plot, the loop inconsistency approach, and node splitting all identified the same treatment
loops as potential sources of inconsistency in the network. However, the loop inconsistency and node splitting approaches
are able to formally test inconsistency in loops. Therefore, in this example, node-splitting is advantageous over the net
heat plot because it not only assesses all the treatment loops in the network but is also able to formally test for evidence
of important inconsistency.
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7 CONCEPTUAL CRITIQUE OF THE NET HEAT PLOT
The net heat plot aims to identify a specific design (or designs) that drive inconsistency in a network. However, locating
inconsistency to a specific design (or even a pair of designs) is a difficult and sometimes impossible task since inconsistency
arises from comparisons between at least three designs. In a three-treatment network, inconsistency can only be identified
and not actually located. Thus, any attempt to locate inconsistency within designs is potentially misleading, in particular
because it may tend to attribute inconsistency to areas with less evidence. For example, in Figure 5, the difference in the
shades of yellow suggests that inconsistency is most important in the Seq CT v Con CT treatment comparison. However,
the Seq CT v Con CT comparison has the least amount of direct evidence, and therefore, the decomposition of Q has
attributed the inconsistencymainly to this comparison.We expect something similar would also happen inmore complex
networks.
Within a network one (or more) deviating direct comparison(s) may affect the network estimates of other comparisons,
producing hot spots of inconsistency, ie, treatment comparisons responsible for inconsistency in one or more treatment
loops.12 The very concept of a “hot spot” is not clearly defined by Krahn et al,12 and the asymmetric nature of the net
heat plot makes interpretation harder. In addition, Krahn et al12 were unclear about how the intensity of color in the net
heat plot relates to important, clinically meaningful inconsistency. For example, in Figure 5, the yellow colors indicate
Qdiffc,d > 0. However, for our lung cancer network, there are no areas of vibrant red, so it may be reasonable to conclude
that there is no meaningful inconsistency in the lung cancer network, in contrast to Section 6.1.
Inconsistency is a loop property; it does notmake sense at the level of an individual design. Further, it cannot be linked to
a specific design in the loop unless at least one design is part of more than one loop. In other words, locating inconsistency
within a network depends on the structure of the network, and no simple method works for all networks. Identifying
inconsistency will depend to some extent on the network connectedness and the number of treatments and trial designs.
Indeed, if more than one design deviates from the true effect, then it is possible that inconsistency might be masked.
Similarly, inconsistency might be harder to spot in a fully connected network, where there are numerous pathways of
indirect evidence, than in a network with fewer direct (and indirect) connections.
Unlike Q, Qhet, and Qinc, which follow chi-squared distributions, Qdiffc,d as the difference between two approximately
chi-square distributed, correlated components, has a nonstandard distribution and is therefore hard to interpret. Complex
calculations would be required to calculate the sampling distribution and obtain a p-value. One possibility would be to
use bootstrapping, but since Qdiffc,d does not have a natural interpretation, we did not pursuethis.
Ideally, what is needed is a way to combine the graphical approach utilized by the net heat plot with the results of
the formal statistical tests implemented in the node-splitting and loop inconsistency approaches to produce a graphically
accessible way for identifying inconsistency in networks.
8 DISCUSSION
Inconsistency in a network can lead to biased treatment effect estimates; therefore, it is important that attempts are made
to identify, understand, and adjust for inconsistency. There aremanymethods for assessing inconsistency in NMA. In this
paper, we considered five of the most popular methods from the simplest method of loop inconsistency9 to more complex
models such as the inconsistency parameter approach10 and the graphical net heat approach.12
The net heat plot calculates the change in inconsistency across the network caused by relaxing the consistency
assumption for each design. The change in inconsistency is known as Qdiffc,d , and these values are displayed graphically in
the net heat plot. We derived a formula for Qdiffc,d , which could be applied to a network in which two treatments are both
directly compared with other treatments to quantify the amount of inconsistency in the network using the net heat plot.
We have shown thatQdiffc,d can be difficult to interpret and, in some cases, amisleadingmeasure of inconsistency. In the spe-
cial case of three-treatment networks, it is approximately an arbitrary scaled version of the difference between the direct
and the indirect evidence, which explains why, in the lung cancer example, the net heat plot did not identify the same
possibility of inconsistency as the analyses in Section 6.1. We advise that the net heat plot is interpreted with caution.
The net heat plot uses Cochran's Q statistic8 in a fixed effect framework and decomposes it into within-trial and
between-trial heterogeneity. This reflects the fact that heterogeneity and inconsistency can be considered as different
aspects of heterogeneity, where inconsistency is the discrepancy between results of single studies and predictions based
on a consistency model.12 The within-trial and between-trial heterogeneity statistics are assumed to follow chi-squared
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distributions. The lung cancer example showed little evidence of heterogeneity, and therefore, it was appropriate, for this
example, to use a fixed effect model that assumed that there was no heterogeneity within designs. Although more com-
plex, the calculations in Section 4.2 could be conducted using a random effects model, and this may be more appropriate
when heterogeneity is present in a network. However, further investigation is required to determine how the net heat plot
identifies inconsistency when heterogeneity is present.
In this paper, we have shown through simulation that inconsistency in larger networks may be hidden when using the
net heat plot alone (Figure 4).We have also shown that the statistics onwhich the net heat plot is built are sensible in some
scenarios but have a somewhat arbitrary weighting. In all scenarios, they are scaled versions of the loop inconsistency
test statistic and as such have scaled chi-squared distributions. However, as Hoaglin27 discusses, the Q statistics only
approach the chi-squared distribution if the study sizes are large (mainly because the standard errors are generally not
known but estimates), which may not be the case in many meta-analyses. While this can be important in applications,
it does not invalidate our arguments in this paper. Therefore, in all situations, the statistics behind the net heat plot are
unintuitive, awkward to interpret, and do not lend themselves to statistical testing. Furthermore, we have shown that
the statistics underpinning the net heat plot can neither generally identify designs causing inconsistency nor are they
necessarily relatively large if inconsistency is present. Hence, inconsistency in larger networks may be hidden when the
net heat plot is used on its own to identify inconsistency. Therefore, it may be that no one method should be considered
alone for assessing inconsistency and that a combination of approaches is the best way forward although this introduces
the challenge of interpreting potentially conflicting results from multiple tests.
Throughout this paper, except for the diabetes network, we assumed all networks contained two-arm trials only, and the
indirect evidence for a design was assumed to come from pathways involving one additional treatment only. While this is
unlikely to be true in larger networks, the weighting of the indirect evidence gets smaller as more additional treatments
are involved so the contribution of longer pathways to the indirect evidence is minimal. Furthermore, we have shown that
the net heat approach can be misleading when only considering two arm trials. Therefore, given the added complexity of
including multiarm trials in a network, it is likely that interpreting the net heat plot will only become more problematic
with increasing network complexity.
Using the loop inconsistency approach to test for inconsistencywithin each loop leads to problemswithmultiple testing
and can be cumbersome in networks with many treatment loops. By contrast, the inconsistency parameter approach is
straight forward to incorporate within most NMA models and quantifies inconsistency but does not provide a straight
forward way for locating the inconsistency. In large networks, the net heat plot is straight forward to implement, and
the provision of freely available user-friendly software is likely to increase the popularity of the approach. Previously,
node-splitting was cumbersome in large networks as each comparison of interest requires a separate model. However,
a decision rule that chooses which comparisons to split, only selecting comparisons in potentially inconsistent loops
but ensuring that all potentially inconsistent loops in the network are investigated, has eliminated most of the manual
work involved in using the node-splitting approach, even in large networks.28 Furthermore, node-splitting has the added
advantage over the net heat approach of being able to statistically test for evidence of inconsistency.
Othermethods of assessing inconsistencywhich have not been considered in this paper include the design-by-treatment
interaction model,5,29 random inconsistency effects,30-34 factorial analysis of variance,35 generalized linear mixed
models,36,37 and the two-stage approach.38 Furthermore, if covariates are distributed unevenly between trials, then incon-
sistency may be reduced by adjusting for covariates.39,40 For a review of methods for assessing inconsistency in NMA,
we recommend Donegan et al.15 All methods to assess inconsistency should be interpreted cautiously, taking the clinical
context into account.
In MA, forest plots can be used to check for outlying single studies and highly weighted studies, which can both be
influential. In NMAwhere evidence for a treatment comparison comes from several sources, a forest plot may not provide
all the information necessary for assessing influential trials or designs. Additional complexity arises when a network
includes multiarm trials. Therefore, careful exploratory work plus presenting the results as in Figure 2 are the key rather
than the net heat plot.41 Furthermore, recent work to reduce the cumbersome nature of using node-splitting in large
networks28 means that an accessible graphical display of node-splitting results may be the graphical representation of
inconsistency that analysts need to identify inconsistency in theirNMAs.
It is important that attempts are made to identify, understand, and adjust for inconsistency in a network. The net heat
plot is an arbitrary weighting of the loop inconsistency statistics, which does not lend itself to statistical testing and can
mask inconsistency in larger networks. We advise that the net heat plot is used with caution. Alternative graphical meth-
ods to the net heat plot, which appropriately assess the amount of inconsistency within a network and display the results
graphically, clearly highlighting influential and inconsistent designs, are needed.
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